Imunon, Inc. Business Combination, Acquisition Related Costs
Imunon, Inc. (IMNN) reported Business Combination, Acquisition Related Costs of $1.39 million for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2016-03-30
- Imunon, Inc. business combination, acquisition related costs for the quarter ending 2014-12-31 was $198.00K.
- Imunon, Inc. business combination, acquisition related costs for the quarter ending 2014-09-30 was $120.00K.
- Imunon, Inc. business combination, acquisition related costs for the quarter ending 2014-06-30 was $1.07M.
- Imunon, Inc. business combination, acquisition related costs for fiscal 2014 was $1.39M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2014-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $318.00K derived: sum of 2 quarters · filed 2016-03-30 | $1.39M derived: sum of 3 quarters · filed 2016-03-30 | $1.39M 10-K · filed 2016-03-30 |
| 2014-09-30 | $120.00K 10-Q · filed 2015-11-05 | $1.19M derived: sum of 2 quarters · filed 2015-11-05 | $1.19M 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $1.07M 10-Q · filed 2015-08-10 | $1.07M 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |